Replacement therapy in patients with hereditary antithrombin III deficiency. 1991

D Menache
Blood Services, American Red Cross, National Headquarters, Washington, DC 20006.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I
D013923 Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. Thromboembolisms
D020152 Antithrombin III Deficiency An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis. Antithrombin 3 Deficiency,Congenital Antithrombin III Deficiency,Deficiency, Antithrombin III,Hereditary Antithrombin Deficiency,Antithrombin 3 Deficiencies,Antithrombin III Deficiencies,Deficiencies, Antithrombin 3,Deficiencies, Antithrombin III,Deficiency, Antithrombin 3

Related Publications

D Menache
October 1989, Transfusion medicine reviews,
D Menache
January 1987, Developments in biological standardization,
D Menache
September 1990, [Rinsho ketsueki] The Japanese journal of clinical hematology,
D Menache
January 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
D Menache
December 1988, Thrombosis and haemostasis,
D Menache
November 2015, Anaesthesia and intensive care,
D Menache
January 1984, The Netherlands journal of medicine,
Copied contents to your clipboard!